Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal

被引:19
作者
Blanck, HM [1 ]
Khan, LK [1 ]
Serdula, MK [1 ]
机构
[1] Ctr Dis Control & Prevent, Div Nutr & Phys Activ, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA
关键词
obesity; prescriptions (drug); Behavioral Risk Factor Surveillance System;
D O I
10.1016/j.ypmed.2004.04.040
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. Despite the popularity of antiobesity medications, there is a lack of population-based data on their use. In addition, response (termination of pill use and receipt of an echocardiogram) to the fenfluramine and dexfenfluramine market withdrawal among the public has not been described. Lessons learned from this event have implications for future withdrawals. Methods. We used data from the Behavioral Risk Factor Surveillance System (BRFSS) a random-digit telephone survey. In 1998, six states included detailed questions about the use of prescription weight loss pills in the previous 2 years, n = 16,460 noninstitutionalized adults aged 18 years or older. Results. Almost one third of prescription weight loss pills users were not obese before taking pills. Family and friends and other nonphysicians were reported as sources of medication by one in ten users. One third of users also reported taking nonprescription diet products. Among fenfluramine or dextenfluramine users, one third continued pill use after the market withdrawal and only one quarter received echocardiograms. Conclusions. Despite enormous publicity, many persons continued to use fen-phen after the market withdrawal and most did not receive follow-up echocardiograms. Our study raises issues regarding the effectiveness of withdrawal warnings in a small but significant subset. Additional means of communicating risk to individuals are needed for future product withdrawals including special strategies for those lacking healthcare coverage. Published by The Institute For Cancer Prevention and Elsevier Inc.
引用
收藏
页码:1243 / 1248
页数:6
相关论文
共 23 条
[1]  
[Anonymous], 1998, Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults
[2]   Use of nonprescription weight loss products - Results from a multistate survey [J].
Blanck, HM ;
Khan, LK ;
Serdula, MK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (08) :930-935
[3]   Correlates of body weight in the 1994 National Population Health Survey [J].
Cairney, J ;
Wade, TJ .
INTERNATIONAL JOURNAL OF OBESITY, 1998, 22 (06) :584-591
[4]   Valvular heart disease associated with fenfluramine-phentermine [J].
Connolly, HM ;
Crary, JL ;
McGoon, MD ;
Hensrud, DD ;
Edwards, BS ;
Edwards, WD ;
Schaff, HV .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588
[5]   Prevention of bacterial endocarditis - Recommendations by the American Heart Association [J].
Dajani, AS ;
Taubert, KA ;
Wilson, W ;
Bolger, AF ;
Bayer, A ;
Ferrieri, P ;
Gewitz, MH ;
Shulman, ST ;
Nouri, S ;
Newburger, JW ;
Hutto, C ;
Pallasch, TJ ;
Gage, TW ;
Levison, ME ;
Peter, G ;
Zuccaro, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (22) :1794-1801
[6]  
*FOOD DRUG ADM, 1997, FDA PUBL HLTH ADV RE
[7]   Characteristics of survey participants with and without a telephone: Findings from the third National Health and Nutrition Examination Survey [J].
Ford, ES .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (01) :55-60
[8]   Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials [J].
Haddock, CK ;
Poston, WSC ;
Dill, PL ;
Foreyt, JP ;
Ericsson, M .
INTERNATIONAL JOURNAL OF OBESITY, 2002, 26 (02) :262-273
[9]  
*IMS AM, 1997, NAT PERSCR AUD PLYM
[10]   Socioeconomic status and weight control practices among 20- to 45-year-old women [J].
Jeffery, RW ;
French, SA .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1996, 86 (07) :1005-1010